Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 165

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 165
---
 and value
for oncologists and other physicians, adoption of its molecular diagnostic tests could be impaired, and DiamiR may not be able to obtain
coverage and adequate reimbursement for them.

In the future, DiamiR may rely on third parties to process and transmit claims to payers for its clinical services, and any delay in processing or transmitting could have an adverse effect on its revenue and financial condition.

As part of its future commercialization efforts, DiamiR may hire third
parties to provide overall processing of claims and to transmit actual claims to payers based on specific payer billing formats. If claims
for its clinical services are not submitted to payers on a timely basis, or if DiamiR is again required to switch to a different third-party
processor to handle claim submissions, DiamiR may experience delays in its ability to process claims and receive payment from payers,
which could have a material adverse effect on its business, financial condition and results of operations.

DiamiR recognizes that there are inherent risks associated with third-party relationships, which may adversely affect its business.

DiamiR expects to continue to depend on third-party service providers
for the foreseeable future, but DiamiR recognizes that there are inherent risks associated with these third-party relationships. For example,
its reputation may be harmed by allegations of wrong-doings or violations of regulations by the third-party service providers. The security
of its confidential and sensitive business information may be breached if the third-party service providers do not exercise high standard
of care to guard and protect the information that comes to their possession because of the relationships with us. DiamiR does not have
control over the amount of time and effort and level of care its third-party service providers will devote to performing their responsibilities
under DiamiRs agreements with them.

<div align='center'>87</div>

If DiamiR is unable to use or maintain its trademarks and trade names or build brand recognition in its markets of interest, its business may be adversely affected.

DiamiR’s US Federal trademarks for the marks CogniMIR
and DiamiR have been registered by the USPTO. If DiamiR does not maintain any registrations granted by the USPTO,
DiamiR may encounter difficulty in continuing to use or enforce such trademarks. DiamiR’s trademarks or trade names may be challenged,
infringed, circumvented, declared generic/descriptive or determined to be infringing on other marks. As a means to enforce its trademark
rights and prevent infringement